cohere.Chat {
	id: a2a9a79c-3c62-4336-92c7-d7f6b6f54a6d
	response_id: a2a9a79c-3c62-4336-92c7-d7f6b6f54a6d
	generation_id: 50df5028-8eed-4b37-bb83-bbdb3726c76c
	message: What other cancers would be amenable to ImmTAC treatment?
	text: Several types of cancer appear to be amenable to ImmTAC treatment, with uveal melanoma being the most prevalent.

Uveal melanoma is the most common intraocular cancer in adults and metastatic uveal melanoma has a poor prognosis. ImmTAC treatments have included tebentafusp-tebn, which has been demonstrated to enhance overall survival and progression-free survival in comparison to single-agent pembrolizumab, ipilimumab, or dacarbazine in untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma patients. 

Moreover, tebentafusp (a soluble T cell receptor fused to an anti-CD3 single-chain fragment) has recently demonstrated success in uveal melanoma. Tebentafusp functions by targeting cells presenting a human leukocyte antigen-A*02:01 complexed with a peptide derived from the melanoma-associated antigen gp100, which is expressed strongly by melanoma cells, weakly by normal melanocytes, and minimally by other tissues. The anti-CD3 domain of tebentafusp redirects CD3+ T cells and other immune cells to the melanoma cells.

Overall, the clinical potential for ImmTAC treatments, such as tebentafusp, in oncology is significant and warrants further investigation.
	conversation_id: None
	prompt: None
	chat_history: None
	preamble: None
	client: <cohere.client.Client object at 0x7f0ac66461d0>
	token_count: {'prompt_tokens': 1616, 'response_tokens': 271, 'total_tokens': 1887, 'billed_tokens': 284}
	meta: {'api_version': {'version': '1'}}
	is_search_required: None
	citations: [{'start': 72, 'end': 86, 'text': 'uveal melanoma', 'document_ids': ['doc_5:1', 'doc_36:1', 'doc_23:0', 'doc_14:2']}, {'start': 114, 'end': 128, 'text': 'Uveal melanoma', 'document_ids': ['doc_23:0']}, {'start': 136, 'end': 176, 'text': 'most common intraocular cancer in adults', 'document_ids': ['doc_23:0']}, {'start': 181, 'end': 228, 'text': 'metastatic uveal melanoma has a poor prognosis.', 'document_ids': ['doc_23:0']}, {'start': 261, 'end': 277, 'text': 'tebentafusp-tebn', 'document_ids': ['doc_23:0']}, {'start': 310, 'end': 334, 'text': 'enhance overall survival', 'document_ids': ['doc_23:0']}, {'start': 339, 'end': 364, 'text': 'progression-free survival', 'document_ids': ['doc_23:0']}, {'start': 382, 'end': 436, 'text': 'single-agent pembrolizumab, ipilimumab, or dacarbazine', 'document_ids': ['doc_23:0']}, {'start': 440, 'end': 532, 'text': 'untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma patients.', 'document_ids': ['doc_23:0']}, {'start': 545, 'end': 556, 'text': 'tebentafusp', 'document_ids': ['doc_5:1', 'doc_36:1', 'doc_14:2']}, {'start': 557, 'end': 627, 'text': '(a soluble T cell receptor fused to an anti-CD3 single-chain fragment)', 'document_ids': ['doc_36:1']}, {'start': 665, 'end': 680, 'text': 'uveal melanoma.', 'document_ids': ['doc_5:1', 'doc_36:1', 'doc_23:0', 'doc_14:2']}, {'start': 706, 'end': 842, 'text': 'targeting cells presenting a human leukocyte antigen-A*02:01 complexed with a peptide derived from the melanoma-associated antigen gp100', 'document_ids': ['doc_36:1']}, {'start': 853, 'end': 952, 'text': 'expressed strongly by melanoma cells, weakly by normal melanocytes, and minimally by other tissues.', 'document_ids': ['doc_36:1']}, {'start': 957, 'end': 1056, 'text': 'anti-CD3 domain of tebentafusp redirects CD3+ T cells and other immune cells to the melanoma cells.', 'document_ids': ['doc_36:1']}, {'start': 1071, 'end': 1160, 'text': 'clinical potential for ImmTAC treatments, such as tebentafusp, in oncology is significant', 'document_ids': ['doc_23:0', 'doc_14:2']}]
	documents: [{'id': 'doc_5:1', 'snippet': " This approach \nhas been explored in a number of cancer types and has recently demonstrated \nsuccess in uveal melanoma. Tebentafusp, a first in class ImmTAC \n(Immune-mobilizing monoclonal TCRs against cancer), has now shown an overall \nsurvival benefit when compared to investigator's choice. This review aims to \nsummarize the experience with this first in class bi-specific T cell engager as \nwell as highlight bi-specifics as a novel treatment strategy in uveal melanoma.\n\nÂ© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.\n\nDOI: 10.1038/s41417-022-00442-9\nPMID: 35236927 [Indexed for MEDLINE]\n", 'title': '35236927'}, {'id': 'doc_36:1', 'snippet': ' In contrast to cutaneous melanoma, kinase \ninhibitors and immune checkpoint inhibitors are usually ineffective in patients \nwith metastatic uveal melanoma. Tebentafusp is a novel form of immunotherapy \nbased on the immune-mobilising monoclonal T cell receptor against cancer \n(ImmTAC) platform, which comprises a soluble T cell receptor that is fused to an \nanti-CD3 single-chain variable fragment. The T cell receptor domain of \ntebentafusp targets cells present a human leukocyte antigen-A*02:01 complexed \nwith a peptide derived from the melanoma-associated antigen gp100, which is \nexpressed strongly by melanoma cells, weakly by normal melanocytes and minimally \nby other tissues. The anti-CD3 domain recruits CD3+ T cells (and, indirectly, \nother immune cells), redirecting these to the melanoma cells.', 'title': '31336704'}, {'id': 'doc_23:0', 'snippet': '1. J Adv Pract Oncol. 2022 Sep;13(7):717-723. doi: 10.6004/jadpro.2022.13.7.8.\nEpub  2022 Oct 12.\n\nTebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal \nMelanoma.\n\nHua G(1), Carlson D(2), Starr JR(1).\n\nAuthor information:\n(1)Geisinger Enterprise Pharmacy, Danville, Pennsylvania.\n(2)Geisinger Cancer Institute, Danville, Pennsylvania.\n\nUveal melanoma is the most common intraocular cancer in adults. Metastatic uveal \nmelanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new \nimmune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T \ncell-directed therapy. Tebentafusp-tebn has been shown in a randomized phase III \nclinical trial to lead to improved overall survival and progression-free \nsurvival when compared with single-agent pembrolizumab, ipilimumab, or \ndacarbazine in previously untreated human leukocyte antigen \n(HLA)-A*02:01-positive metastatic uveal melanoma patients.', 'title': '36199496'}, {'id': 'doc_14:2', 'snippet': "\n(9)Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), \nArnold-Heller-Str. 3, 24105 Kiel, Germany.\n(10)Department of Dermatology, Comprehensive Cancer Center (Westdeutsches \nTumorzentrum), German Cancer Consortium (DKTK, partner site Essen) and \nUniversity Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany.\n\nTebentafusp is a new T cell receptor bispecific fusion protein and the first \napproved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) \nmetastatic uveal melanoma, with a proven benefit in overall survival versus the \ninvestigator's choice. As a first-in-class therapeutic option, this Immune \nmobilising monoclonal T cell receptor Against Cancer (ImmTAC) is associated with \na new adverse event (AE) profile. Based on clinical experience, a national \nexpert group discussed recommendations for tebentafusp treatment, focusing on AE \nmanagement.", 'title': '37595494'}]
	search_results: None
	search_queries: [{'text': 'cancers amenable to ImmTAC treatment', 'generation_id': '066a9338-a5e7-42b1-887c-82b4e2fbc9d3'}]
}
